Connect Biopharma Holdings Limited Increase (Decrease) in Accounts Receivable
Connect Biopharma Holdings Limited (CNTB) reported Increase (Decrease) in Accounts Receivable of $2.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-12
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $2.94M.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$13.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$4.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $17.00K, a 99.66% decline year-over-year.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for fiscal 2025 was -$776.00K, a 198.35% decline from fiscal 2024.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for fiscal 2024 was $789.00K.
- Connect Biopharma Holdings Limited increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.92M 10-Q · filed 2026-08-12 | $2.92M derived: sum of 3 quarters · filed 2026-08-12 | $2.94M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$13.00K 10-Q · filed 2026-05-12 | -$17.00K derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | -$8.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $13.00K derived: sum of 2 quarters · filed 2026-03-31 | $5.00K derived: sum of 3 quarters · filed 2026-08-12 | -$776.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.00K derived: sum of 2 quarters · filed 2026-08-12 | -$772.00K 10-Q · filed 2025-11-12 | -$5.00M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$789.00K 10-Q · filed 2026-08-12 | -$5.02M derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$781.00K 10-Q · filed 2026-05-12 | -$5.01M derived: sum of 2 quarters · filed 2026-05-12 | $8.00K derived: sum of 3 quarters · filed 2026-05-12 | $8.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $789.00K derived: sum of 2 quarters · filed 2026-03-31 | $789.00K derived: sum of 3 quarters · filed 2026-03-31 | $789.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $5.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.02M derived: sum of 2 quarters · filed 2025-11-12 | $5.02M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |